The decrease of p-mTOR was also found to be significant in HER2-positive patients compared with HER2-negative patients, indicating that the PI3K/Akt/mTOR pathway may be suppressed more effectively by chemotherapy in HER2-positive breast cancers. Here, PIK3CA is linked to breast cancer.